Calithera Biosciences names new board member
This article was originally published in Scrip
Executive Summary
Calithera Biosciences, a clinical-stage pharmaceutical company developing small-molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, has named H Ward Wolff to its board of directors, where he will chair the company's audit committee. Mr Wolff is currently executive vice-president and chief financial officer of Sangamo BioSciences.